Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 5, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Homozygous Familial Hypercholesterolemia
Interventions
BIOLOGICAL

Evolocumab

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

Trial Locations (21)

1200

Research Site, Brussels

2193

Research Site, Johannesburg

7100

Research Site, La Louvière

7925

Research Site, Observatory

8011

Research Site, Christchurch

10032

Research Site, New York

14004

Research Site, Córdoba

21000

Research Site, Dijon

27003

Research Site, Lugo

28040

Research Site, Madrid

45227

Research Site, Cincinnati

56124

Research Site, Pisa

75651

Research Site, Paris

N6A 5K8

Research Site, London

G7H 7K9

Research Site, Chicoutimi

656 91

Research Site, Brno

500 05

Research Site, Hradec Králové

686 01

Research Site, Uherské Hradiště

Unknown

Research Site, New Territories

0000

Research Site, Beirut

1105 AZ

Research Site, Amsterdam

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY